Literature DB >> 19096876

Saccharomyces boulardii in childhood.

Yvan Vandenplas1, Oscar Brunser, Hania Szajewska.   

Abstract

INTRODUCTION: Probiotics are live microorganisms which confer a health benefit on the host. Saccharomyces boulardii, a yeast, has been found to be an effective probiotic in double-blind placebo-controlled randomized clinical studies.
MATERIALS AND METHODS: We reviewed the established mechanisms of actions and clinical efficacy in children of S. boulardii.
CONCLUSIONS: The mechanisms of action of S. boulardii depend mainly on the inhibition of some bacterial toxins, anti-inflammatory effects, and on stimulating effects on the intestinal mucosa such as trophic effects on the brush border enzymes and immunostimulatory effects. At present, in pediatric populations, there is evidence that S. boulardii is beneficial for the treatment of acute gastroenteritis and the prevention of antibiotic-associated diarrhea. More data are needed in other indications such as traveller's diarrhea, Helicobacter pylori eradication, and inflammatory bowel disease. S. boulardii is a yeast strain that has been extensively studied in vitro and in vivo. Recent data have opened the door for new therapeutic indications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19096876     DOI: 10.1007/s00431-008-0879-7

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  78 in total

1.  Effect of a probiotic food as an adjuvant to triple therapy for eradication of Helicobacter pylori infection in children.

Authors:  Cinthia G Goldman; Domingo A Barrado; Norma Balcarce; Eduardo Cueto Rua; Masaru Oshiro; María L Calcagno; Mariana Janjetic; Julián Fuda; Ricardo Weill; María J Salgueiro; Mauro E Valencia; Marcela B Zubillaga; José R Boccio
Journal:  Nutrition       Date:  2006-09-15       Impact factor: 4.008

2.  Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy.

Authors:  J L Tong; Z H Ran; J Shen; C X Zhang; S D Xiao
Journal:  Aliment Pharmacol Ther       Date:  2007-01-15       Impact factor: 8.171

3.  Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea.

Authors:  A G Billoo; M A Memon; S A Khaskheli; G Murtaza; Khalid Iqbal; M Saeed Shekhani; Ahson Q Siddiqi
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

4.  Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria.

Authors:  M F Bernet; D Brassart; J R Neeser; A L Servin
Journal:  Gut       Date:  1994-04       Impact factor: 23.059

5.  Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children.

Authors:  H Szajewska; A Skórka; M Dylag
Journal:  Aliment Pharmacol Ther       Date:  2007-02-01       Impact factor: 8.171

6.  Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes.

Authors:  Guillaume Dalmasso; Françoise Cottrez; Véronique Imbert; Patricia Lagadec; Jean-François Peyron; Patrick Rampal; Dorota Czerucka; Hervé Groux; Arnaud Foussat; Valerie Brun
Journal:  Gastroenterology       Date:  2006-12       Impact factor: 22.682

7.  Effect of Lactobacillus strains and Saccharomyces boulardii on persistent diarrhea in children.

Authors:  David Gaón; Hugo García; Luis Winter; Nora Rodríguez; Ricardo Quintás; Silvia N González; Guillermo Oliver
Journal:  Medicina (B Aires)       Date:  2003       Impact factor: 0.653

8.  Lack of relationship of Clostridium difficile to antibiotic-associated diarrhea in children.

Authors:  C L Elstner; A N Lindsay; L S Book; J M Matsen
Journal:  Pediatr Infect Dis       Date:  1983 Sep-Oct

9.  Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants.

Authors:  J P Buts; G Corthier; M Delmee
Journal:  J Pediatr Gastroenterol Nutr       Date:  1993-05       Impact factor: 2.839

10.  Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study.

Authors:  Mehmet Cindoruk; Gulbanu Erkan; Tarkan Karakan; Ayse Dursun; Selahattin Unal
Journal:  Helicobacter       Date:  2007-08       Impact factor: 5.753

View more
  17 in total

Review 1.  Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.

Authors:  Lynne V McFarland
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

2.  Probiotics in pediatrics.

Authors:  Meenakshi Bothra; Shinjini Bhatnagar
Journal:  Indian J Pediatr       Date:  2015-02-19       Impact factor: 1.967

3.  Probiotic yeasts: anti-inflammatory potential of various non-pathogenic strains in experimental colitis in mice.

Authors:  Benoît Foligné; Joëlle Dewulf; Pascal Vandekerckove; Georges Pignède; Bruno Pot
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

4.  Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial.

Authors:  Hassan Seddik; Hanae Boutallaka; Ilham Elkoti; Fouad Nejjari; Reda Berraida; Sanaa Berrag; Khaoula Loubaris; Sara Sentissi; Ahmed Benkirane
Journal:  Eur J Clin Pharmacol       Date:  2019-01-29       Impact factor: 2.953

5.  Clinical efficacy comparison of Saccharomyces boulardii and yogurt fluid in acute non-bloody diarrhea in children: a randomized, controlled, open label study.

Authors:  Makbule Eren; Ener C Dinleyici; Yvan Vandenplas
Journal:  Am J Trop Med Hyg       Date:  2010-03       Impact factor: 2.345

Review 6.  Clinical practice: Helicobacter pylori infection in childhood.

Authors:  Deniz Ertem
Journal:  Eur J Pediatr       Date:  2012-09-27       Impact factor: 3.183

Review 7.  Probiotic sepsis in preterm neonates-a systematic review.

Authors:  Tithi Kulkarni; Swati Majarikar; Mangesh Deshmukh; Anitha Ananthan; Haribalakrishna Balasubramanian; Anthony Keil; Sanjay Patole
Journal:  Eur J Pediatr       Date:  2022-03-29       Impact factor: 3.183

8.  Prophylactic Saccharomyces boulardii versus nystatin for the prevention of fungal colonization and invasive fungal infection in premature infants.

Authors:  Gamze Demirel; Istemi Han Celik; Omer Erdeve; Sibel Saygan; Ugur Dilmen; Fuat Emre Canpolat
Journal:  Eur J Pediatr       Date:  2013-05-24       Impact factor: 3.183

9.  Antimicrobial and probiotic properties of yeasts: from fundamental to novel applications.

Authors:  Rima Hatoum; Steve Labrie; Ismail Fliss
Journal:  Front Microbiol       Date:  2012-12-19       Impact factor: 5.640

10.  Comparison of safety, effectiveness and serum inflammatory factor indexes of Saccharomyces boulardii versus Bifidobacterium triple viable in treating children with chronic diarrhea: a randomized trial.

Authors:  Jiawei Zhang; Su Wan; Qingqing Gui
Journal:  Transl Pediatr       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.